Orchid Pharma Q1 FY27 Monitoring Report: No Deviation in QIP Proceeds

Orchid Pharma Ltd has submitted its Monitoring Agency Report for Q1 FY27 (ended June 30, 2026), prepared by CARE Ratings Limited. The report confirms that the utilization of proceeds from the Qualified Institutions Placement (QIP) of ₹400 crores has no deviation from the stated objects. The company revised the allocation of QIP proceeds among the objects, and the monitoring agency has reviewed this in relation to the QIP's objectives. The report is in compliance with SEBI regulations.